Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

set by lower apatorsen manufacturing costs due to the timing of manufacturing activities.
  • Net loss for the second quarter and six months ended June 30, 2013 was $8.4 million, or $0.57 per diluted common share, and $15.1 million, or $1.03 per diluted common share, respectively. Net loss for the second quarter and six months ended June 30, 2012 was $4.2 million, or $0.29 per diluted common share, and $11.1 million, or $0.89 per diluted common share, respectively. The net loss in the six months ended June 30, 2013 included a non-cash gain on revaluation of the warrant liability of $2.3 million. 
  • The Company had $57.0 million in cash, cash equivalents and short-term investments as of June 30, 2013, compared to $75.4 million as of December 31, 2012.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 - $50 million.
  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of June 30, 2013 will be sufficient to fund its currently planned operations into 2015.
  • At August 8, 2013, The Company had 14,680,395 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended June 30,Six months ended June 30,2013201220132012Collaboration revenue

    $
    ,340$
    2,429$
    ,416$
    3,745Operating expenses:  Research and development

    13,2636,32624,11811,408  General and administrative

    2,4732,0474,9733,784Total operating expenses

    15,7368,37329,09115,192Loss from operations

    (9,396)(5,944)(17,675)(11,447)  Other income (expense)

    9761,7292,558372Net loss

    $
    (8,420)$
    (4,215)$
    (15,117)$
    (11,075)Basic and diluted net loss per share

    $
    (0.57)$
    (0.29)$
    (1.03)$<
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... May 05, 2015 Research and Markets ... "Home Healthcare Global Market - Forecast to 2020" ... healthcare market is expected to reach more than $300+ ... The home healthcare equipment market is expected to ... services market. Home healthcare is gaining a tremendous attention ...
    (Date:5/5/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... for the three months ended March 31, 2015 compared ... million for the same period in 2014.  Isis, significantly ... milestone payments earned from its partners compared to the ... reported a loss from operations of $9.3 million for ...
    (Date:5/5/2015)... May 5, 2015 Big Market Research presents ... Europe , ( France , ... Spain , UK) and Japan . Current ... The report provides the 5-year test volume and sales forecasts by ... Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT ...
    Breaking Medicine Technology:Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 132015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3
    ... Pa., Oct. 27, 2011 ViroPharma Incorporated (NASDAQ: ... has signed a definitive agreement to acquire DuoCort ... Sweden focused on improving glucocorticoid replacement therapy.  The ... ViroPharma,s orphan disease commercial product pipeline.  The company ...
    ... Oct. 27, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... 30, 2011. In the third quarter of 2011, we: ... representing 21 percent growth over the third quarter of 2010; ... quarter and $184 million for the 9 month period,  representing Cinryze ...
    Cached Medicine Technology:ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline 2ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline 3ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline 4ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline 5ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline 6ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline 7ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 2ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 3ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 4ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 5ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 6ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 7ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 8ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 9ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 10ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 11ViroPharma Incorporated Reports Third Quarter 2011 Financial Results 12
    (Date:5/5/2015)... ProTexting, LLC – a premier ... Mobile Engagement Campaigns and other Mobile solutions, introduces e-mail ... now leverage the power of Mobile Marketing to expand ... e-mail addresses into the Constant Contact Platform. , ProTexting ... growing trend of multi-channel marketing would become more prominent ...
    (Date:5/5/2015)... Freeport, Grand Bahama (PRWEB) May 05, 2015 ... published its Orthopedic Lifestyle Report today. The study was ... orthopedic conditions such as osteoarthritis and sports-related ... chronic pain and stiffness was the most prevalent symptom ... reduced functionality such as walking, standing and bending over. ...
    (Date:5/5/2015)... SC (PRWEB) May 05, 2015 On May, ... episode with Charleston musician Irene Rose about alternatives for youngsters ... Rose, “How did you get the idea for starting a ... replies, “I run an entertainment company called Once Upon a ... them moral lessons through songs and even scripture. We play ...
    (Date:5/5/2015)... California (PRWEB) May 05, 2015 On ... Downtown Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s ... Durkin, LA’s leading producer of sustainable product placement in ... of the world’s top providers of ecologically sound and ... a premier red carpet event that makes appearances at ...
    (Date:5/5/2015)... For the growing list of high temperature ... loggers. This data logger series is based on ... optimum performance throughout exposure to high temperatures and submersion without ... capable of storing up to 32,700 readings and feature a ... year or longer. All data loggers in the HiTemp140 series ...
    Breaking Medicine News(10 mins):Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6
    ... prohibited by international law and professional associations, and yet ... do, argue two bioethicists. Their timely paper in the ... the trail leading to the death of Osama Bin ... subject to "enhanced interrogation techniques," which many believe amounted ...
    ... (DDW) is the largest international gathering of physicians, ... hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by ... Diseases, the American Gastroenterological Association (AGA) Institute, the ... for Surgery of the Alimentary Tract, DDW takes ...
    ... Reporter , MONDAY, May 9 (HealthDay News) -- An estimated ... -- has an autism spectrum disorder, a new study says ... United States. Estimates of autism prevalence in the United ... 110 children, or less than 1 percent. But those ...
    ... A key step in the processing of HIV within cells ... cells can recognize and destroy infected cells. Researchers at ... that as HIV proteins are broken down within cells, ... destruction by CD8 T cells there is a great ...
    ... EDITOR,S PICK: Sensitizing prostate cancer to radiotherapy ... spread locally from inside the prostate to immediately ... However, disease recurs in approximately half of these ... treatment and thereby decrease the incidence of disease ...
    ... to assist the hungry, including food banks and providing ... short-term, emergency solutions. Those who rely on these programs ... lead to poor diet choices, nutritional deficiencies and health ... the production of sustainable, locally grown foods is key ...
    Cached Medicine News:Health News:A grim dilemma: Treating the tortured prisoner 2Health News:A grim dilemma: Treating the tortured prisoner 3Health News:UNC research highlights at 2011 Digestive Disease Week 2Health News:S. Korean Study Suggests Autism Rate May Be Much Higher 2Health News:S. Korean Study Suggests Autism Rate May Be Much Higher 3Health News:Step in breakdown of HIV proteins essential to recognition, destruction of infected cells 2Health News:JCI online early table of contents: May 9, 2011 2Health News:JCI online early table of contents: May 9, 2011 3Health News:JCI online early table of contents: May 9, 2011 4Health News:JCI online early table of contents: May 9, 2011 5Health News:JCI online early table of contents: May 9, 2011 6Health News:JCI online early table of contents: May 9, 2011 7Health News:JCI online early table of contents: May 9, 2011 8Health News:Availability of local food key to improving food security 2
    The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
    ... is a wearable CPAP (Continuous Positive Airway ... apnea. The lightweight BreatheX CPAP device (patent ... its built-in, rechargeable battery, and is mobile, ... longer need to be "plugged in to ...
    Paraffin Block Storage System...
    Shandon Paraffin Block Cabinet...
    Medicine Products: